Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN

Squamous cell lung carcinoma (SCC) accounts for 30% of patients with NSCLC and to date, no molecular targeted agents are approved for this type of tumor. However, recent studies have revealed several oncogenic mutations in SCC patients, including an alteration of the PI3K/AKT pathway, i.e. PI3K poin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavazzoni, Andrea, La Monica, Silvia, Alfieri, Roberta, Ravelli, Andrea, Van Der Steen, Nele, Sciarrillo, Rocco, Madeddu, Denise, Lagrasta, Costanza Anna Maria, Quaini, Federico, Bonelli, Mara, Fumarola, Claudia, Cretella, Daniele, Digiacomo, Graziana, Tiseo, Marcello, Peters, Godefridus J., Ardizzoni, Andrea, Petronini, Pier Giorgio, Giovannetti, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581093/
https://www.ncbi.nlm.nih.gov/pubmed/28881794
http://dx.doi.org/10.18632/oncotarget.18087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581093/
https://www.ncbi.nlm.nih.gov/pubmed/28881794
http://dx.doi.org/10.18632/oncotarget.18087

Ejemplares similares